Fentanyl: A General Approach

Main Article Content

Rodrigo Marín-Navarrete
Felipe Cortés-Salazar
Carmen Fernández-Cáceres

Abstract

Fentanyl is a synthetic opioid from the phenylpiperidine group, 100 times more potent than morphine and 50 times more potent than heroin (Walter, 2023). It is currently the drug of first choice for general sedation, as it presents a lower risk of surgical respiratory arrest and post-surgical physical dependence. However, despite its specific therapeutic uses and due to its mechanism of action, it is a substance that, if consumed without medical supervision, can cause addiction in those who consume it. Sustained and abusive use of fentanyl affects health and, at the mental level, can generate symptoms such as decreased impulse control, alterations in thought content (delusions, paranoia), and sensory perception (illusions and hallucinations). At the physical level, it increases the risk of seizures and severe respiratory depression, and, compared to other substances, the risk of overdose and death is higher (Kilwein et al., 2018). Furthermore, it causes neurobiological changes that can persist for decades after cessation of use (Volkow & Blanco, 2023). In conclusion, recreational and illicit fentanyl use represents a major threat to public health.

Published: Jun 27, 2025

Article Details

How to Cite
Marín-Navarrete, R., Cortés-Salazar, F. ., & Fernández-Cáceres, C. (2025). Fentanyl: A General Approach. Revista Internacional De Investigación En Adicciones, 11(1), I-II. https://doi.org/10.28931/riiad.2025.392
Section
Editorial

References

Albores-García, D. & Cruz, S. (2023). Fentayl and other new psychoactive synthetic opioids. Challenges to Prevention and Treatment. Rev. Invest. Clin. 75(3): 93—104. DOI: https://doi.org/10.24875/ric.23000109

Caponnetto, P., Triscari, S., Prezzavento, G. C., Farrugio, G., Farrauto, C., Lanzafame, S., Schilirò, G., Uccelli, E., Vitale, N. M., Fakhrou, A., Nagi, K., & Concerto, C. (2024). Exploring the Psychological Side of Fentanyl: A Scoping Review to Disclose the Psychosocial Dimensions of Illicitly Manufactured Fentanyl Users. Health Psychology Research, 12, 120958. https://doi.org/10.52965/001c.120958

Comisión Nacional de Salud Mental y Adicciones (CONASAMA). Informe sobre la situación de la salud mental y el consumo de sustancias en México 2024. 2024;1–49

Eden, C.O., Alkahalaileh, D.S., Pettersson, D.R., Hunter, A.J. & Arastu, A.H. (2024). Clinical and neuroradiographic features of fentanyl inhalation-induced leukoencephalopathy. BMJ Case Report, 17:e258395. https://doi.org/10.1136/bcr-2023-258395

Goodman-Meza, D., Friedman, J., Kalmin, M. M., Aguilar-Posada, E., Seamans, M. J., Velazquez-Moreno, S., Fleiz, C., Shin, M., Arredondo-Sanchez, J., Strathdee, S. A., & Shoptaw, S. (2021). Geographical and socioeconomic disparities in opioid access in Mexico, 2015-19: a retrospective analysis of surveillance data. The Lancet. Public health, 6(2), e88–e96. https://doi.org/10.1016/S2468-2667(20)30260-7

Kandasamy, R., Hillhouse, T. M., Livingston, K. E., Kochan, K. E., Meurice, C., Eans, S. O., Ming-Hua, Li., Andrew, D. W., Bernard, P. R., Jay, P. M., Susan, L. I., Neil, T. B., Andrew, A., & Traynor, J. R. (2021). Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects. Proceedings of the National Academy of Sciences, 118(16), e2000017118. https://doi.org/10.1073/pnas.2000017118

Kilwein, T. M., Hunt, P., & Looby, A. (2018). A descriptive examination of nonmedical fentanyl use in the United States: Characteristics of use, motives, and consequences. Journal of Drug Issues, 48(3), 409-420. https://doi.org/10.1177/0022042618765726

Krausz, R. M., Westenberg, J. N., & Vogel, M. (2022). Addressing fentanyl use disorder with fentanyl-assisted treatment. The Lancet Psychiatry, 9(2), 103—105. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00393-X/fulltext

Marín-Navarrete, R., Fernández-Caceres, C., Cortés-Salazar, F. & Gonzalez-Pérez, F.J. (2025). Profile of Fentanyl users in healthcare settings in Mexico: sociodemographic and consumption characteristics. (IN PRESS).

NIDA (agosto 2024). Muertes por sobredosis de drogas: Hechos y cifras. Recuperado 18 de marzo 2025 de https://nida.nih.gov/es/areas-de-investigacion/las-tendencias-y-estadisticas/indices-de-muertes-por-sobredosis

Ramos-Matos, C. F., Bistas, K. G., & Lopez-Ojeda, W. (2023). Fentanyl. In StatPearls. StatPearls Publishing.

Volkow, N. D., & Blanco, C. (2023). Fentanyl and other opioid use disorders: Treatment and research needs. American Journal of Psychiatry, 180(6), 410-417. https://doi.org/10.1176/appi.ajp.20230273

Walter, K. (2023). Fentanyl Overdose. JAMA, 329(2), 184. https://doi.org/10.1001/jama.2022.22462